Trial Profile
A Prospective Nonrandomized Study of Autologous Muscle Derived Cell (AMDC) Transplantation for Treatment of Fecal Incontinence
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Iltamiocel (Primary)
- Indications Faecal incontinence
- Focus Adverse reactions
- Sponsors Cook Medical; Cook MyoSite
- 23 Nov 2023 Results of safety and efficacy , published in the Annals of Surgery
- 09 Dec 2021 Status changed from active, no longer recruiting to completed.
- 19 Nov 2021 Planned End Date changed from 1 Nov 2021 to 1 Dec 2021.